Galmed Pharmaceuticals Ltd (GLMD) — Cash Flow-to-Debt Ratio
Galmed Pharmaceuticals Ltd (GLMD) has a Cash Flow-to-Debt Ratio of -0.68x as of December 2025, meaning its operating cash flow of $-1.95 Million could theoretically repay -1% of its total liabilities ($2.85 Million) in one year. See Galmed Pharmaceuticals Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Galmed Pharmaceuticals Ltd Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Galmed Pharmaceuticals Ltd across 14 annual periods. Also explore net asset growth rate of Galmed Pharmaceuticals Ltd to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Galmed Pharmaceuticals Ltd (2012–2025)
Year-by-year debt coverage analysis for Galmed Pharmaceuticals Ltd. For market capitalisation and broader financial context, see Galmed Pharmaceuticals Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.22x | $-6.32 Million | $2.85 Million | ▲ +18.0% |
| 2024 | -2.71x | $-5.88 Million | $2.17 Million | ▼ -21.3% |
| 2023 | -2.23x | $-6.14 Million | $2.75 Million | ▲ +62.1% |
| 2022 | -5.90x | $-18.50 Million | $3.14 Million | ▼ -9.5% |
| 2021 | -5.39x | $-32.89 Million | $6.11 Million | ▼ -68.6% |
| 2020 | -3.19x | $-26.29 Million | $8.23 Million | ▼ -55.8% |
| 2019 | -2.05x | $-14.94 Million | $7.29 Million | ▲ +38.5% |
| 2018 | -3.33x | $-9.02 Million | $2.71 Million | ▼ -6.3% |
| 2017 | -3.14x | $-12.07 Million | $3.85 Million | ▼ -39.0% |
| 2016 | -2.26x | $-12.13 Million | $5.38 Million | ▲ +27.6% |
| 2015 | -3.12x | $-8.47 Million | $2.72 Million | ▲ +48.8% |
| 2014 | -6.09x | $-9.24 Million | $1.52 Million | ▼ -410.6% |
| 2013 | -1.19x | $-2.52 Million | $2.12 Million | ▼ -6.1% |
| 2012 | -1.12x | $-3.08 Million | $2.74 Million | — |